Energy companies sit on a powerful tool that can help.
That unlikely overlap is now turning into a concrete plan in France, where nuclear know‑how meets medical need. The move blends power station discipline with the delicate demands of health supply chains.
The plan at a glance
Framatome and EDF outlined in Paris their intent to use a pressurized water reactor to manufacture cobalt‑60 for healthcare.
The approach places small metal capsules filled with cobalt‑59 into high‑neutron zones inside the core.
Neutrons convert cobalt‑59 into cobalt‑60, which emits high‑energy gamma rays used for sterilization and radiotherapy.
A demonstration loading is penciled in for 2026 to confirm engineering and regulatory steps.
Commercial service is targeted around 2030 if the trial succeeds and approvals follow.
This extra job will not add a single kilowatt to the grid, yet it could support life‑saving care across Europe.
How cobalt‑60 is made inside a power reactor
Engineers start with a stable metal: cobalt‑59.
They seal it inside purpose‑built steel capsules designed to withstand heat, pressure, and neutron bombardment.
➡️ The daily posture mistake that slowly increases shoulder and jaw tension
➡️ Experts analyzed Nivea cream what they found will make you rethink your skincare routine
Capsules sit in positions where the neutron flux is strong and well mapped by the reactor’s physics team.
Months of irradiation convert a share of the material into cobalt‑60 through neutron capture.
Operators then remove the capsules during a planned outage, under strict radiological controls.
The capsules move to specialized facilities where the active material is processed into sealed sources for industry and hospitals.
Cobalt‑60’s half‑life is about 5.27 years, which offers a practical balance between strength and shelf life.
Why electricity production stays unaffected
The capsule holders fit into spare locations engineered for this kind of mission.
They avoid any impact on control rod motion, coolant flow, or neutron moderation.
Scheduling aligns with routine refueling to keep plant availability intact.
Safety cases address thermal limits, material compatibility, and dose rates for workers.
That is why utilities can run the main job—producing low‑carbon electricity—and still deliver medical isotopes on the side.
A tight global market and rising need
About 60% of the world’s cobalt‑60 originates in Canada, with production also in Russia, India, and China.
Geopolitics and logistics shocks have shown how fragile that balance can be for hospitals and sterilization plants.
A European source adds redundancy, shorter lead times, and better predictability for device makers.
Demand keeps growing as more single‑use devices enter operating rooms and clinics worldwide.
Medical sterilization with gamma rays avoids heat and helps protect polymers and electronics from damage.
Regional production strengthens health security by cutting import risks and stabilizing supply for critical care.
What hospitals and industry gain
- More reliable access to high‑activity sources for sterile syringes, implants, and catheters.
- Steady feedstock for radiotherapy devices used in gynecologic and brain cancers.
- Lower transport exposure and fewer customs bottlenecks within the bloc.
- Potentially smoother maintenance cycles for sterilization facilities that plan around source replacement.
- A clearer view of future pricing as capacity diversifies.
What it takes to deliver
Licensing must satisfy nuclear safety regulators and health authorities for pharmaceutical‑grade supply chains.
Cobalt‑60 transport uses Type B packages with robust shielding and security protocols.
Source fabrication demands ISO‑compliant manufacturing, quality control, and traceability down to each capsule.
Facilities must plan for end‑of‑life source return and secure storage to close the loop.
Workforce training matters, from reactor teams to radiopharmacy staff and logistics partners.
Timeline and scale
The 2026 demonstration validates irradiation hardware, dosimetry, and removal workflows.
A go‑decision would unlock commercial batches around 2030 after full licensing.
EDF could expand to additional reactors once the method proves predictable and safe.
Contracts with sterilization firms and hospitals will frame the steady cadence of source deliveries.
Scale depends on neutron availability, outage frequency, and downstream processing capacity.
Beyond cobalt‑60: the wider isotope push
Power reactors and research reactors already carry much of modern medicine’s imaging and therapy on their shoulders.
France’s move fits a bigger trend that blends nuclear engineering with targeted treatments and diagnostics.
| Isotope | Main medical use | Typical production route | Notable trait |
|---|---|---|---|
| Cobalt‑60 | Device sterilization and external radiotherapy | Neutron activation of cobalt‑59 in reactors | Strong gamma emission for deep penetration |
| Technetium‑99m | Nuclear imaging for heart, bone, and cancer scans | Milk‑off from molybdenum‑99 generators | Short half‑life supports same‑day diagnostics |
| Iodine‑131 | Thyroid cancer and hyperthyroidism therapy | Fission products separated from irradiated targets | Beta emissions focused on thyroid tissue |
| Lutetium‑177 | Targeted radioligand therapy for certain tumors | Neutron activation routes with ytterbium or lutetium targets | Combines therapeutic beta with helpful gammas for imaging |
| Yttrium‑90 | Selective internal radiation for liver cancer | Separation from strontium‑90 generators | Microspheres deliver dose inside tumor vasculature |
| Xenon‑133 | Lung ventilation and cerebral blood flow studies | Reactor fission and gas processing | Inert gas inhaled in controlled diagnostic tests |
Risks, trade‑offs, and safeguards
Radiation protection remains front and center from the core to the clinic.
Dose to workers must stay within tight limits during capsule loading and retrieval.
Transport security and real‑time tracking reduce diversion and tampering risk.
End‑of‑life sources return to licensed handlers for recycling or long‑term containment.
Reactor scheduling and outage windows need discipline to match hospital timelines.
Clear rules, predictable outages, and transparent supply contracts will decide whether the plan scales smoothly.
What to watch next
Selection of the host reactor will signal how France spreads the load across its fleet.
Design approvals for capsule holders and handling tools will mark a major gate.
Manufacturing readiness in Europe will matter as much as neutron time in the core.
Health‑sector agreements will reveal volumes, delivery frequency, and service models.
Training and mock‑ups with full remote tooling will set the tone for safe operations.
Extra context for readers
Cobalt‑60’s energy lines around 1.17 and 1.33 MeV enable deep, uniform sterilization through dense packaging.
Ethylene oxide remains a key sterilant for many devices, yet tightening rules push manufacturers to diversify methods.
Gamma capacity closer to end‑users reduces delays when sources age and need swaps to keep dose rates on target.
Hospitals that rely on cobalt‑based radiotherapy benefit from predictable source strength to keep treatment plans consistent.